The cost of adverse event management in patients with RAS wild-type metastatic colorectal cancer treated with first-line cetuximab and panitumumab: An Italian healthcare payer perspective

被引：0
|
作者：
Patterson, K. [1 ]
Bhattacharyya, S. [1 ]
Personeni, N. [2 ]
Gebbia, V. [3 ]
Novelli, P. [4 ]
Di Matteo, S. [5 ]
Colombo, G. [6 ]
Pescott, C. [7 ]
机构：
[1] BresMed, Hlth Econ, Sheffield, S Yorkshire, England
[2] Humanitas Univ, Dept Biomed Sci, Milan, Italy
[3] Univ Palermo, La Maddalena Hosp, Palermo, Italy
[4] Merck Serono SpA, HTA & Market Access, Rome, Italy
[5] SAVE Studi Anal Valutaz Econ srl, Hlth Econ & Outcomes Res, Milan, Italy
[6] Univ Pavia, Dept Drug Sci, Pavia, Italy
[7] Merck Healthcare KGaA, Global Evidence & Value Dev, Darmstadt, Germany
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
596P
引用
收藏
页码：225 / 225
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial
    Wang, Huijuan
    Huang, Lingfei
    Gao, Peng
    Zhu, Zhengyi
    Ye, Weifeng
    Ding, Haiying
    Fang, Luo
    BMJ OPEN, 2020, 10 (02):
  • [22] Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer
    Han, Jiaqi
    Xiao, Desheng
    Tan, Chongqing
    Zeng, Xiaohui
    Hu, Huabin
    Zeng, Shan
    Jiang, Qin
    She, Longjiang
    Yao, Linli
    Li, Li
    Tang, Lanhua
    Ma, Jian
    Huang, Jin
    Shen, Liangfang
    CANCER CONTROL, 2020, 27 (01)
  • [23] Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer
    Hocking, Christopher M.
    Price, Timothy J.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2014, 7 (01) : 20 - 37
  • [24] First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer
    Ohta, Katsuya
    Ikenaga, Masakazu
    Uemura, Mamoru
    Sakata, Kazuya
    Nishimura, Junichi
    Hata, Taishi
    Matsuda, Chu
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Mori, Masaki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 216 - 216
  • [25] Tolerability on Serious Adverse Events of First-Line Bevacizumab and Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
    Han, Yu Na
    Choi, Yeo Jin
    Rhie, Sandy Jeong
    HEALTHCARE, 2022, 10 (02)
  • [26] First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer
    Uemura, Mamoru
    Kim, Ho Min
    Hata, Tsuyoshi
    Sakata, Kazuya
    Okuyama, Masaki
    Takemoto, Hiroyoshi
    Fujii, Hitoshi
    Fukuzaki, Takayuki
    Morita, Tetsushi
    Hata, Taishi
    Takemasa, Ichiro
    Satoh, Taroh
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Mori, Maski
    MOLECULAR AND CLINICAL ONCOLOGY, 2016, 5 (02) : 375 - 379
  • [27] A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US
    Graham, Christopher N.
    Christodoulopoulou, Alexandra
    Knox, Hediyyih N.
    Sabatelli, Lorenzo
    Hechmati, Guy
    Garawin, Tamer
    Strickler, John H.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (11) : 1075 - 1083
  • [28] Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters
    Geoffrey Y. Ku
    Benjamin A. Haaland
    Gilberto de Lima Lopes
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 231 - 238
  • [29] Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters
    Ku, Geoffrey Y.
    Haaland, Benjamin A.
    Lopes, Gilberto de Lima, Jr.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (02) : 231 - 238
  • [30] Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial
    Kasper, Stefan
    Meiler, Johannes
    Knipp, Heike
    Hohler, Thomas
    Reimer, Peter
    Steinmetz, Tilman
    Berger, Winfried
    Linden, Gabriele
    Reis, Henning
    Markus, Peter
    Paul, Andreas
    Dechene, Alexander
    Schumacher, Brigitte
    Kostbade, Karina
    Virchow, Isabel
    Ting, Saskia
    Worm, Karl
    Schmid, Kurt W.
    Herold, Thomas
    Wiesweg, Marcel
    Schuler, Martin
    Trarbach, Tanja
    CLINICAL COLORECTAL CANCER, 2020, 19 (04) : 236 - +
12345